A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

Summary

The main purpose of this study is to investigate the efficacy and safety of XW003 versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise alone

Timeline

Start

2022-12-29

Primary completion

2024-06-12

Completion

2024-10-12

Publications

• Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, Shi B, Pang S, Wang K, Shi X, Zhang X, Fu L, Liu Y, Lu Y, Huang D, Jiang C, Pan T, Xue H, Han J, Ding H, Bing S, Jiang F, Zheng Q, Yang M, Guan L, Liu X, Ning J, Bu Y, Guo M, Yang L, Guo W, Li Y, Xu S, Pan H. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026 Jan 7;17(1):1420. doi: 10.1038/s41467-025-68165-7.

Drugs

Indications